Vivotif contains not less than 2 x 109 viable organisms of the attenuated Salmonella typhi strain Ty 21a Berna. As a result of an irreversible change in cell wall biosynthesis, this registered strain is completely devoid of pathogenicity but retains its full immunogenic capacity.
Oral, active immunization against typhoid fever. New investigations also showed a cross-immunity against S. paratyphi B. Provides triple (local, cellular and systemic) protection for children ≥3 years.
1 cap, irrespective of age, on days 1, 3 and 5, 1 hr before a meal, with a cold or lukewarm drink (water, milk).
As with other vaccines, the administration of Vivotif is not recommended for children <3 months.
Duration of Immunity: Protection commences 2 weeks after taking the last capsule and lasts for at least 3 years. When travelling from non-endemic to endemic areas, a booster dose of vaccine is recommended if >1 year has elapsed since the last immunization.
Congenital and acquired immune deficiency, including treatment with immunosuppressive and antimitotic drugs, acute febrile illness and acute intestinal infection. Safety of the vaccination during pregnancy has not yet been established.
Certain antibiotics as well as sulfonamides are active against Salmonellae. These products should not be given simultaneously with Vivotif.
Other inoculations, including live vaccines, may be administered at the same time.
Safety of the vaccination during pregnancy has not yet been established.
In very rare cases, mild gastrointestinal disturbances or a transitory exanthema may occur.
Vivotif may interact with immunosuppressives, immunoglobulins, blood products, sulfonamides and certain antibiotics.
Store between +2°C and +8°C in a dry place. Protect from light.
J07AP01 - typhoid, oral, live attenuated ; Belongs to the class of typhoid bacterial vaccines.